Introduce Ultragenyx’s leadership to government, discuss policies related to rare disease therapies including B.C.'s life sciences strategy, and where opportunities may align for the government and Ultragenyx to support rare-disease patients.
|
-
Development or enactment of any regulation, including the enactment of a regulation for the purposes of amending or repealing a regulation
-
Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
-
Awarding, amendment or termination of any contract, grant or financial benefit by or on behalf of the government of British Columbia or a Provincial entity
-
Decision by the Executive Council or a member of the Executive Council to transfer from the Crown for consideration all or part of, or any interest in or asset of, any business, enterprise or institution that provides goods or services to the Crown, a Provincial entity or the public
-
Decision by the Executive Council or a member of the Executive Council to have the private sector instead of the Crown provide goods or services to the government of British Columbia or a Provincial entity
|
Health
|